Fibromyalgia is one of the harder chronic pain conditions to manage. The drug menu — duloxetine, pregabalin, milnacipran, plus physical therapy — helps some patients but not others. That gap drives interest in off-label HBOT.
The data for HBOT in fibromyalgia is real but small. One trial, one group of women, one research team. This page lays out what that trial showed and what it did not show.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | NOT approved for fibromyalgia |
| UHMS classification | Not on the 14 approved indications list |
| Medicare coverage | NOT covered for fibromyalgia |
| Insurance coverage | Out-of-pocket only at most clinics |
| Typical out-of-pocket | $6,000-$12,000 for a 40-session course |
| Evidence grade | Low — one small RCT, no replication |
The evidence
Fibromyalgia HBOT rests on one notable randomized trial. Independent replication is absent.
The Efrati and colleagues 2015 PLoS ONE trial, PMID 26010952 enrolled 60 women with fibromyalgia. The crossover design ran 40 HBOT sessions at 2.0 ATA. Patients in the HBOT arm reported symptom gains, and SPECT imaging showed brain activity changes.
The trial was sponsored by a single Israeli research group. It used a crossover with delayed-treatment control, not a sham. That design has been criticized for not blinding patients to whether they were getting active HBOT.
A 2023 meta-analysis of HBOT for fibromyalgia, PMID 37218804 pooled four trials with 163 patients. The pooled data suggested modest gains in tender point count and impact scores. The authors flagged small sample sizes and risk of bias.
A Yildiz and colleagues 2004 trial, PMID 15174219 ran a small randomized study in 50 patients. The HBOT arm showed lower tender point counts and pain scores. The trial was a single Turkish center and small.
A 2022 PMC review of HBOT for fibromyalgia reached a similar caveat-heavy conclusion. The signal exists. The trials are too few and too small for routine practice.
A 2023 PLoS ONE trial comparing HBOT to drugs in fibromyalgia patients with traumatic brain injury history found HBOT improved pain scores more than medication. The population was narrow and the trial was again single-center.
The Bennett and colleagues Cochrane review framework, 2018 on chronic pain HBOT noted the same limits across pain conditions. Small trials, single-center designs, and high risk of bias.
The American College of Rheumatology fibromyalgia management resources do not list HBOT as a recommended therapy. The EULAR revised recommendations for fibromyalgia, 2016, PMID 27377815 also do not include HBOT.
The pattern is clear. One promising trial, a handful of small follow-ups, no specialty body endorsement, and no insurance coverage.
Why people pursue this anyway
Fibromyalgia patients often cycle through many drugs without lasting relief. The FDA-approved options — duloxetine, pregabalin, milnacipran — have small effect sizes and real side effects.
That care gap is real. Patients reading the 2015 Efrati trial see a 60-woman study with symptom gains and brain changes. The marketing pull is easy to see.
Wellness clinics including Restore Hyper Wellness and a long tail of small operators market HBOT to fibromyalgia patients. Press coverage of the 2015 trial is still cited a decade later.
The honest gap is that one promising trial is not the same as a settled treatment. Patients deserve to weigh that gap against a five-figure spend.
For deeper context, see our analysis of institutional silence on HBOT and our evidence-vs-marketing breakdown of the leading HBOT chain.
What rheumatology guidelines actually say
The American College of Rheumatology, the US specialty body, does not list HBOT in its fibromyalgia care guide. The European League Against Rheumatism 2016 guide also leaves HBOT off the list.
UHMS does not list fibromyalgia on its 14 approved indications. The UHMS HBO indications page, 2024 is the source of truth.
Major academic pain centers do not run HBOT plans for fibromyalgia. Their wound care and dive medicine chambers run for the approved uses only.
The silence reflects evidence quality. One unreplicated single-center trial does not move guidelines. Patients should know this before paying out of pocket.
Cost versus evidence
A 40-session course at a wellness clinic runs $6,000 to $12,000. Premium chain packages can run higher.
Patients face this cost without insurance support. HSA and FSA accounts may or may not accept the claim, depending on plan rules.
That price stacks against one promising 60-patient trial. The math poses a hard question — is one PLoS ONE paper worth a five-figure spend, or would the same money go further on guideline-backed care?
The framing is not that no patient should try this. The framing is that the evidence does not justify the marketing-implied confidence.
What to ask your rheumatologist
Patients weighing HBOT for fibromyalgia can ask a few key questions. Each cuts through clinic marketing.
What is the FDA approval status for this use — the answer is "not approved." How many independent groups have replicated the Efrati 2015 trial — the answer is "very few, all small." What does my rheumatologist think — most are skeptical and prefer guideline-backed options first.
For chamber-type details, see our hard-shell vs soft-shell chamber explainer. The Efrati protocol uses medical-grade hard chambers from makers such as Sechrist Industries and Perry Baromedical, not the soft 1.3 ATA chambers from OxyHealth or Summit to Sea found at many wellness sites. Some wellness chains run ETC Biomedical chambers too.
Distinguishing from FDA-approved uses
Fibromyalgia sits in a different place from approved HBOT uses. The approved list — carbon monoxide poisoning, dive injury, stubborn bone infection, diabetic foot wounds, and ten more — all have decades of backing data and multi-center trials.
Our diabetic foot ulcer evidence atlas and carbon monoxide poisoning evidence atlas show what real FDA-approved HBOT evidence looks like — multiple independent trials, settled mechanism, insurance coverage.
Fibromyalgia does not have that backing yet. The honest call is "investigational" and let patients decide with eyes open.
Frequently asked questions
Is HBOT FDA-approved for fibromyalgia?
No. The FDA recognizes 14 conditions for HBOT and fibromyalgia is not among them. The UHMS approved indications list, current 2024, also does not include fibromyalgia.
What does the Efrati 2015 trial actually show?
The trial reported symptom gains and brain activity changes in 60 women with fibromyalgia after 40 HBOT sessions. The design was a crossover with delayed-treatment control rather than a sham. No large independent group has replicated the findings in the years since.
Will Medicare or insurance cover this?
Generally no. Medicare and most commercial plans cover HBOT only for the 14 approved indications. Fibromyalgia is out-of-pocket at almost all clinics offering this protocol.
How much does a course cost?
Most wellness clinics charge $200 to $350 per session. A 40-session course runs $6,000 to $12,000. Premium chain packages can run higher.
What do rheumatologists say?
The American College of Rheumatology fibromyalgia resources and the European League Against Rheumatism 2016 guidelines do not include HBOT. Most rheumatologists prefer guideline-backed options first.
Sources
- Efrati and colleagues PLoS ONE 2015, PMID 26010952
- Meta-analysis on HBOT for fibromyalgia 2023, PMID 37218804
- PMC HBOT for fibromyalgia review, 2022
- PLoS ONE HBOT vs drugs in fibromyalgia with TBI history, 2023
- Bennett HBOT chronic pain framework, 2018, PMID 30144258
- Yildiz fibromyalgia trial 2004, PMID 15174219
- EULAR fibromyalgia recommendations 2016, PMID 27377815
- American College of Rheumatology Fibromyalgia Resources
- UHMS HBO Indications List, 2024
Medical disclaimer
This page is medical journalism and not medical advice. HBOT for fibromyalgia is an investigational off-label use without FDA approval. Standard fibromyalgia care including guideline-recommended medications and physical therapy remains the first-line path. Talk to your rheumatologist before pursuing any out-of-pocket HBOT protocol. This page does not diagnose, treat, or substitute for professional medical care.